Amgen Says Repatha Reduced Major Cardiovascular Event Risk by 31% in Diabetes Patients

MT Newswires Live03-30

Amgen (AMGN) said Saturday that its cholesterol-lowering drug Repatha reduced the risk of first major cardiovascular events by 31% in high-risk diabetes patients without known significant atherosclerosis.

The company said that the findings came from a subgroup analysis of 3,655 patients in the phase 3 VESALIUS-CV trial followed for a median of 4.8 years.

Repatha was added to statins or other LDL-cholesterol-lowering therapies, Amgen said. The drug reduced the risk of coronary heart disease death, heart attack or ischemic stroke versus placebo, it added.

It also reduced a broader composite endpoint that included ischemia-driven revascularization by 31%, according to Amgen.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap
Leave a comment